← Eichor
Study identifier: NCT06682325 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Pharmaco-proteomic Platform to Evaluate Drug Interactions in Liver Transplant Patients

Condition: Drug-drug Interaction · Liver Transplantation  ·  Sponsor: Pontificia Universidad Catolica de Chile

PhaseN/A
Planned participants48
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this observational study is to enhance the ability to forecast kidney failure in liver transplant patients in the ICU under multidrug treatment by developing a computer platform that integrates mathematical models of drug interactions, proteomics, and clinical data. The main outcomes it aims to develop are: 1. Design the multidrug web computing platform with available information on drug pair interactions (DDIs). 2. Integrate the proteomic and clinical data of liver transplant patients into the IT platform. 3. Implement the multidrug web platform to predict the clinical evolution of liver transplant patients.

This description comes directly from the study's public registry record.

Talk to the study team

Nelson Barrera, PhD  ·  56987687058  ·  nbarrerr@uc.cl

Always discuss trial participation with your own doctor first.

Locations (3)

Hospital ClínicoUC-ChristusSantiago, Santiago Metropolitan, ChileRecruiting
Pontificia Universidad Católica de ChileSantiago, Santiago Metropolitan, ChileActive Not Recruiting
Universidad de ValparaísoValparaíso, Valparaiso, ChileActive Not Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06682325